submitted by /u/mvea [link] [comments] |
Profits drive the rising prices of MS drugs in the US, finds a new study based on interviews with four pharmaceutical executives published in Neurology. In Europe, the price of a drug is typically highest when it launches and declines over time. The opposite appears to be the case in the US.
Subscribe to:
Post Comments (Atom)
Subscribe UsPopular Posts
|
No comments:
Post a Comment